Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · KREBS BIOCHEMICALS & IND · 7 November 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
KREBS BIOCHEMICALS & IND
NSE: KREBSBIO · BSE: 524518
NSE: KREBSBIO · BSE: 524518
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
KREBS BIOCHEMICALS & IND
StateQ2 FY27 filed
Last close · 6 Nov 2026₹57.50
Market cap₹0.1k cr
TTM P/E · P/B · EV/EBITDA— · — · —
KREBS BIOCHEMICALS & IND is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 53 | 52 | 50 | 43 | 24 |
| EBITDA (ex other income) | (41) | (16) | (9) | (15) | (5) |
| margin % | (77.0) | (30.3) | (17.3) | (34.7) | (23.0) |
| Owners' profit | (45) | (25) | (20) | (27) | (17) |
| EPS, as reported (₹) | (20.81) | (11.30) | (9.16) | (12.49) | (7.85) |
| ROE % · ROCE % | 59.3 · (35.0) | 24.8 · (17.3) | 16.5 · (12.9) | 18.4 · (32.1) | 10.4 · (19.6) |
| Debt / equity (x) | (1.90) | (1.84) | (1.62) | (1.45) | (1.38) |
| Cash from operations | (17) | (26) | 2 | (8) | (2) |
| Capex | (27) | (11) | (8) | (5) | (4) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · KREBS BIOCHEMICALS & IND · 7 November 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11 | 6 | 5 | 4 | 7 | 7 | 7 | 6 |
| Profit before tax | (8) | (8) | (5) | (6) | (3) | (2) | (2) | (5) |
| Net profit | (8) | (8) | (5) | (6) | (3) | (2) | (2) | (5) |
| EPS (₹) | (3.59) | (3.83) | (2.47) | (2.85) | (1.45) | (1.09) | (1.15) | (2.50) |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,46,270 | 40.7 | 4.98 | 24.9 | 5.5 | 8.0 | 11.8 | 29.3 |
| DIVI S LABORATORIES LTD | 2,73,493 | 93.6 | 16.32 | 79.4 | 15.3 | 18.8 | 8.7 | 40.7 |
| TORRENT PHARMACEUTICALS L | 1,80,500 | 80.2 | 9.82 | 42.6 | 6.0 | 4.0 | 11.8 | 33.5 |
| LAURUS LABS LIMITED | 1,26,430 | 94.3 | 20.45 | 72.4 | 12.9 | 14.2 | 7.2 | 34.0 |
| ZYDUS LIFESCIENCES LTD | 1,19,550 | 28.8 | 3.94 | 15.4 | 6.4 | 6.8 | 12.4 | 24.0 |
| DR. REDDY S LABORATORIES | 1,14,646 | 40.9 | 2.93 | 18.5 | 3.4 | 4.2 | 12.1 | 19.9 |
| CIPLA LTD | 1,13,988 | 39.3 | 3.21 | 19.3 | 4.6 | 6.2 | 8.0 | 18.7 |
| MANKIND PHARMA LIMITED | 1,04,902 | 46.8 | 5.88 | 30.6 | 7.2 | 7.3 | — | 27.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| ROCE | (24.1) | 7.7 | 168 of 177 | 5% |
| EBITDA margin | (33.3) | 14.6 | 171 of 178 | 4% |
| Revenue growth | 38.9 | 17.1 | 34 of 163 | 80% |
| Profit growth | 12.1 | 21.8 | 90 of 157 | 43% |
| Market cap | 124 | 814 | 130 of 181 | 28% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · KREBS BIOCHEMICALS & IND · 7 November 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 30 Oct 2026 · Revenue rises, but quarterly loss increases from June | compliance | minimal | — | — |
| 29 Oct 2026 · Q2 revenue rises 39%, but net loss persists at Rs 539.85 lakh | results | high | — | — |
| 29 Oct 2026 · September quarter revenue rises 39%, but loss persists as Vizag unit stays shut | results | high | — | — |
| 16 Oct 2026 · Board meeting on Oct 29, 2026 to consider Q2 and H1 FY26 results | board shareholder meetings | low | — | — |
| 5 Oct 2026 · RTA certifies demat and remat details for Q2 FY27 under SEBI reg 74(5) | compliance | minimal | — | — |
| 29 Sept 2026 · 34th AGM: All 5 resolutions passed, RPT with Ipca Labs cleared | compliance | minimal | — | — |
| 29 Sept 2026 · Outcome of 34th AGM held via video conferencing on Sept 29, 2026 | board shareholder meetings | low | — | — |
| 21 Sept 2026 · Trading window closed for Q2 FY27 results at Krebs Biochemicals | compliance | minimal | — | — |
| 7 Sept 2026 · Newspaper notice published for 34th AGM on 29 September 2026 | compliance | minimal | — | — |
| 4 Sept 2026 · 34th AGM on Sep 29, 2026; seeks nod for Rs 120 Cr Ipca Labs related party deals | board shareholder meetings | medium | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in